


## Cardiac $Ca_v1.2$ channels require $\beta$ subunits for $\beta$ -adrenergic-mediated modulation but not trafficking

Lin Yang, ... , Henry M. Colecraft, Steven O. Marx

*J Clin Invest.* 2018. <https://doi.org/10.1172/JCI123878>.

Research In-Press Preview Cardiology Muscle biology

### Graphical abstract



Find the latest version:

<https://jci.me/123878/pdf>



## **Cardiac Cav1.2 channels require $\beta$ subunits for $\beta$ -adrenergic-mediated modulation but not trafficking**

Lin Yang<sup>1,+</sup>, Alexander Katchman<sup>1,+</sup>, Jared Kushner<sup>1,+</sup>, Alexander Kushnir<sup>1,+</sup>, Sergey I. Zakharov<sup>1</sup>, Bi-xing Chen<sup>1</sup>, Zunaira Shuja<sup>2</sup>, Prakash Subramanyam<sup>2</sup>, Guoxia Liu<sup>1</sup>, Arianne Papa<sup>2</sup>, Daniel Roybal<sup>3</sup>, Geoffrey S. Pitt<sup>4</sup>, Henry M. Colecraft<sup>2,3</sup>, Steven O. Marx<sup>1,3,\*</sup>

From the <sup>1</sup>Division of Cardiology, Department of Medicine, Columbia University, Vagelos College of Physicians and Surgeons, New York, NY 10032; <sup>2</sup>Department of Physiology and Cellular Biophysics, and <sup>3</sup>Department of Pharmacology, Columbia University, Vagelos College of Physicians and Surgeons, <sup>4</sup>Cardiovascular Research Institute, Weill Cornell Medical College

**Running title:** Adrenergic regulation of Ca<sup>2+</sup> channels and cardiac contractility

<sup>+</sup>equal contribution

\* Correspondence and requests for materials:

Steven Marx, MD

Columbia University, Vagelos College of Physicians and Surgeons

622 W168th Street

PH-3 Center

New York, NY 10032

212-305-0271

Email: [sm460@cumc.columbia.edu](mailto:sm460@cumc.columbia.edu)

The authors have declared that no conflict of interest exists.

## ABSTRACT

Ca<sup>2+</sup> channel  $\beta$ -subunit interactions with pore-forming  $\alpha$ -subunits are long-thought to be obligatory for channel trafficking to the cell surface and for tuning of basal biophysical properties in many tissues. Unexpectedly, we demonstrate that transgenic expression of mutant cardiac  $\alpha_{1C}$  subunits lacking capacity to bind Ca<sub>v</sub> $\beta$  because of alanine-substitutions of three conserved residues— Y467, W470 and I471 in the  $\alpha$ -interaction domain of rabbit  $\alpha_{1C}$  – can traffic to the sarcolemma in adult cardiomyocytes *in vivo* and sustain normal excitation-contraction coupling. However, these  $\beta$ -less Ca<sup>2+</sup> channels cannot be stimulated by  $\beta$ -adrenergic pathway agonists, and thus adrenergic-augmentation of contractility is markedly impaired in isolated cardiomyocytes and in hearts. Similarly, viral-mediated expression of a  $\beta$ -subunit-sequestering-peptide sharply curtailed  $\beta$ -adrenergic stimulation of wild-type Ca<sup>2+</sup> channels, identifying an approach to specifically modulate  $\beta$ -adrenergic regulation of cardiac contractility. Our data demonstrate that  $\beta$  subunits are required for  $\beta$ -adrenergic regulation of Ca<sub>v</sub>1.2 channels and positive inotropy in the heart, but are dispensable for Ca<sub>v</sub>1.2 trafficking to the adult cardiomyocyte cell surface, and for basal function and excitation-contraction coupling.

## INTRODUCTION

In heart cells,  $\text{Ca}^{2+}$  influx via  $\text{Ca}_v1.2$  channels mediates excitation-contraction (E-C) coupling, controls action potential duration, and regulates gene expression.  $\text{Ca}_v1.2$  channels are multi-subunit proteins composed minimally of a pore-forming  $\alpha_{1C}$  and regulatory  $\beta$  and  $\alpha_{2\delta}$  subunits (1-4). In adult ventricular cardiomyocytes, most  $\text{Ca}_v1.2$  channels localize to transverse tubules where they lie in close proximity ( $\sim 12$  nm) and apposed to ryanodine receptors (RyR2) at dyadic junctions (5). Dysregulation of  $\text{Ca}_v1.2$  activity, surface density, or sub-cellular localization in cardiomyocytes can result in cardiac arrhythmias, heart failure, and sudden death.

Reconstitution experiments concluded that binding to  $\beta$  subunits is indispensable for  $\alpha_{1C}$  trafficking to the cell surface (6-14). The physiological relevance of this finding was initially supported by  $\beta_2$  knockout mice, which were embryonic lethal, likely secondary to a decreased L-type  $\text{Ca}^{2+}$  current (15). An initial idea that  $\beta$  binding to the  $\alpha$ -interaction domain (AID) of the  $\alpha_1$ -subunit I-II loop shielded an ER retention signal in the I-II loop to allow forward trafficking of the channel proved inadequate in subsequent experiments (9, 16-18). Surprisingly, cardiomyocyte-specific, conditional deletion of the *Cacnb2* gene in adult mice reduced  $\beta_2$  protein by 96% but caused only a modest 29% reduction in  $\text{Ca}^{2+}$  current, with no obvious cardiac impairment (19). Interpretation of this result is ambiguous, however, as it is complicated by the remnant ( $\sim 4\%$ )  $\beta_2$  expression as well as the presence other  $\text{Ca}_v\beta$  isoforms expressed in adult cardiomyocytes (13). Moreover, a contrasting viewpoint was provided by a study in which shRNA-mediated knockdown of  $\beta_2$  in adult rat myocytes substantially diminished  $\text{Ca}^{2+}$  current (20).

To definitively address the controversies regarding the role of  $\beta$  subunits in mediating trafficking and regulation of  $\text{Ca}^{2+}$  channels in the heart, we created transgenic mice lines with three mutations in the AID, which renders the pore-forming  $\alpha_{1C}$  subunit incapable of binding  $\beta$  subunits.

With this new model, we definitively demonstrate *in vivo* that  $\beta$  subunit binding to  $\alpha_{1C}$  is not required for trafficking and that the basal function of  $\beta$ -less  $\text{Ca}^{2+}$  channels is only minimally altered.

Instead, we found that the  $\beta$  subunit is obligatory for transducing  $\beta$ -adrenergic signals to cardiac  $\text{Ca}_v1.2$  channels. Cardiac  $\text{Ca}_v1.2$  channels are prominently up-regulated by  $\beta$ -adrenergic agonists via activation of protein kinase A (PKA) (21, 22) as part of the fundamental flight or fight response, yet the detailed mechanisms by which PKA activates  $\text{Ca}_v1.2$  remain unknown despite several decades of investigation. We recently eliminated the long-presumed pore-forming  $\alpha_{1C}$  subunit as the relevant PKA target with a comprehensive alanine substitution of all consensus, conserved PKA phosphorylation sites (>22 serines/threonines) *in vivo* (23). Prior studies also “ruled out” a contribution for the  $\beta$  subunit as substitution or elimination of potential PKA phosphorylation sites did not perturb  $\beta$ -adrenergic regulation (24-27), although other consensus PKA sites are present in the N-terminal regions of the protein. We found that  $\beta$  subunit binding to  $\alpha_{1C}$ , but not PKA phosphorylation of  $\beta$ , is absolutely essential for the augmentation of  $\text{Ca}^{2+}$  current and cardiac contractile response to  $\beta$ -adrenergic-PKA stimulation. These findings identify the key regulatory mechanisms impacting  $\beta$ -adrenergic regulation of  $\text{Ca}^{2+}$  influx and contractility in the heart.

## RESULTS

### $\beta$ -less Cav1.2 channels traffic to membrane in adult cardiomyocytes

Alanine-substitutions of three conserved residues– Y467, W470 and I471– in rabbit  $\alpha_{1C}$  AID (Figure 1A) increases the  $K_d$  of  $\beta$  subunit binding from nM to  $> 6M$  (28-31).  $\beta_2$  subunits failed to co-precipitate with the AID-mutant  $\alpha_{1C}$  when co-expressed with AID-mutant  $\alpha_{1C}$  in tsA201 cells (Supplemental Figure 1A) confirming the critical importance of this region for  $\beta$  binding. We then created transgenic mice with cardiac-specific and doxycycline-inducible expression of N-terminal 3X FLAG-tagged dihydropyridine (DHP)-resistant (T1066Y/Q1070M) (32, 33) AID-mutant rabbit  $\alpha_{1C}$  (Figure 1B). Controls were provided by transgenic FLAG-tagged DHP-resistant  $\alpha_{1C}$  subunits with wild-type AIDs, termed pseudo-wild-type (pWT)  $\alpha_{1C}$ . Co-immunoprecipitation experiments from transgenic mice hearts confirmed that pWT  $\alpha_{1C}$  associates with endogenous  $\beta$ -subunit, but AID-mutant  $\alpha_{1C}$  does not (Figure 1C). The anti- $\beta$  antibody recognizes all Cav $\beta$  subunits, thus ruling out compensation from other  $\beta$  subunits in heart and thus confirming that the AID motif is essential to mediate the high-affinity binding between  $\alpha_{1C}$  and  $\beta_2$  in cardiomyocytes.

We assessed the impact of loss of  $\beta$ -binding on AID-mutant  $\alpha_{1C}$  subcellular localization and functional expression in cardiomyocytes using three complementary approaches. First, immunofluorescence experiments using anti-FLAG antibody on fixed cardiomyocytes indicated that both transgenic pWT  $\alpha_{1C}$  and AID-mutant  $\alpha_{1C}$  channels displayed a similar striated pattern consistent with surface membrane distribution and localization in t-tubules (Figure 1D). Second, we exploited the T1066Y/Q1070M mutations that impart relative DHP-resistance (32, 33) to block  $Ca^{2+}$  currents from endogenous DHP-sensitive Cav1.2 with nisoldipine and isolate  $Ca^{2+}$  current from transgenic pWT  $\alpha_{1C}$  or AID-mutant  $\alpha_{1C}$  channels. Compared to cardiomyocytes isolated from NTG control mice, cardiomyocytes isolated from both pWT and AID-mutant  $\alpha_{1C}$  transgenic mice

had increased peak  $\text{Ca}^{2+}$  currents, and substantial peak  $\text{Ca}^{2+}$  currents remaining after exposure to nisoldipine (Figure 1E-F). Third, field-stimulated contraction of cardiomyocytes isolated from transgenic AID-mutant  $\alpha_{1C}$  mice persisted in the presence of 300 nM nisoldipine (Figure 1I-J), similar to the contraction of cardiomyocytes isolated from NTG (Figure 1G) and transgenic pWT  $\alpha_{1C}$  mice (Figure 1H). Overall, these results demonstrate that transgenic  $\beta$ -less AID-mutant  $\alpha_{1C}$  channels traffic to the sarcolemma and trigger E-C coupling in cardiomyocytes.

This result is in stark contrast to the necessary role of  $\beta$ -binding for surface trafficking and function of  $\text{Ca}_v1.2$  channels reconstituted in heterologous cells (Supplemental Figure 1A-B), or expressed in hippocampal neurons (34). We also considered that endogenous WT  $\alpha_{1C}$  channels could couple with AID-mutant  $\alpha_{1C}$  channels to facilitate trafficking of  $\beta$ -less channels to the surface membranes in cardiomyocytes, which could be basis for the observed differences between cardiomyocytes and heterologous expression systems. To determine whether coupling-induced trafficking could occur, we co-expressed either DHP-resistant pWT  $\alpha_{1C}$  or DHP-resistant AID-mutant  $\alpha_{1C}$  with both WT  $\alpha_{1C}$  and  $\beta_2$  subunits in tsA201. In the presence of nisoldipine, which inhibits the WT  $\alpha_{1C}$  channels, tsA201 cells expressing the AID-mutant  $\alpha_{1C}$  channels had no remaining  $\text{Ca}^{2+}$  current (Supplemental Figure 1C, right), while cells expressing the DHP-resistant pWT  $\alpha_{1C}$  had remaining current (Supplemental Figure 1C, left). Thus, at least in tsA201 cells,  $\beta$ -less channels were unable to “hitchhike” to the membrane with WT channels.

### **PKA modulation of $\text{Ca}_v1.2$ channels is dependent upon $\alpha_{1C}$ - $\beta$ interactions**

In heterologous expression studies,  $\beta$  subunits not only enable  $\alpha_{1C}$  surface trafficking, but also can differentially induce, depending upon  $\beta$  subunit isoform, a hyperpolarizing shift in the voltage-dependence of  $\text{Ca}_v1.2$  activation and increase the channel open probability ( $P_o$ ) (12, 27). We

assessed the biophysical properties of the transgenic  $\beta$ -less AID-mutant  $\alpha_{1C}$  channels compared to transgenic pWT  $\text{Ca}^{2+}$  channels. Surprisingly, normalized current-voltage ( $I$ - $V$ ) relationships of nisoldipine-resistant transgenic pWT and AID-mutant  $\alpha_{1C}$  channels were remarkably similar (Figure 2A). The mid-point potentials and slope factors for steady-state activation, derived from a Boltzmann function, demonstrated relatively small shifts for the AID-mutant channels compared to control pWT channels (Figure 2B-C). Furthermore, the inactivation kinetics of nisoldipine-resistant  $\text{Ca}^{2+}$  currents were not significantly different at any test potential between cardiomyocytes isolated from pWT and AID-mutant  $\alpha_{1C}$ , respectively (Figure 2D). Therefore, in adult cardiomyocytes,  $\text{Ca}_v1.2$  channels comprised of transgenic  $\beta$ -less  $\alpha_{1C}$  have similar voltage-dependence of activation and inactivation kinetics as transgenic pWT  $\text{Ca}_v1.2$  channels.

We next determined the sensitivity of  $\text{Ca}_v1.2$  channels containing either transgenic pWT  $\alpha_{1C}$  or AID-mutant  $\alpha_{1C}$  to PKA modulation. In cardiomyocytes isolated from mice expressing transgenic pWT  $\alpha_{1C}$ , 200 nM isoproterenol increased the nisoldipine-insensitive current by a mean of  $1.9 \pm 0.1$ -fold (Figure 2E, G-J), and shifted the  $V_{\text{mid}}$  in the hyperpolarizing direction by a mean of 4.4 mV (Figure 2B). Similarly, forskolin, which directly activates adenylyl cyclase thereby bypassing  $\beta$ -adrenergic receptors, increased transgenic pWT  $\alpha_{1C}$   $\text{Ca}^{2+}$  currents by  $1.8 \pm 0.1$ -fold (Figure 2H-J). In sharp contrast,  $\text{Ca}^{2+}$  currents through transgenic AID-mutant  $\alpha_{1C}$   $\text{Ca}_v1.2$  channels were insensitive to either isoproterenol (Figure 2B,F-G, I-J) or forskolin (Figure 2H-J). In cardiomyocytes, there is an inverse relationship between total peak current and isoproterenol-induced or forskolin-induced fold increase in  $\text{Ca}^{2+}$  current (27). In cardiomyocytes isolated from transgenic pWT  $\alpha_{1C}$  mice, we observed an inverse relationship between total basal current density (prior to nisoldipine) and isoproterenol or forskolin-induced increase in  $\text{Ca}^{2+}$  current (Figure 2J). For the transgenic AID-mutant  $\beta$ -less channels, however, activation of PKA by either forskolin or

isoproterenol had no effect on  $\text{Ca}^{2+}$  current, regardless of basal  $\text{Ca}^{2+}$  current density (Figure 2J).

To address whether the YWI/AAA mutations themselves produced an intrinsic insensitivity of the channel to PKA modulation, we sought to engender conditions under which there would be a predominance of  $\beta$ -less endogenous  $\text{Cav}1.2$  channels in isolated cardiomyocytes. We achieved this by using adenovirus to over-express a YFP-tagged 18-residue AID peptide derived from  $\alpha_{1C}$  I-II loop (or a mutant YWI/AAA peptide as a control) in cultured adult guinea pig ventricular cardiomyocytes. We reasoned this intervention would serve as a sponge for endogenous  $\beta$  subunits, leaving a majority of endogenous  $\text{Cav}1.2$  channels devoid of  $\beta$ . In control cells expressing either GFP or YFP-tagged mutant (YWI/AAA) AID peptide incapable of binding  $\beta$ , 1  $\mu\text{M}$  forskolin resulted in a robust 4- to 5-fold increase in whole-cell current amplitude (Figure 3A,C,D, F-H). By contrast, this response was sharply curtailed in cardiomyocytes over-expressing YFP-AID peptide (Figure 3B,E,G-H). Hence,  $\beta$ -less wild-type  $\alpha_{1C}$  channels also demonstrate a marked insensitivity to PKA modulation.

We also considered two trivial explanations that could potentially account for the insensitivity of AID-mutant  $\alpha_{1C}$  to PKA stimulation: 1) these channels were already phosphorylated by PKA under basal conditions; 2) the  $\beta$ -adrenergic signaling pathway was compromised in cardiomyocytes from AID-mutant  $\alpha_{1C}$  transgenic mice. To address whether transgenic AID-mutant  $\alpha_{1C}$  channels were basally PKA-phosphorylated, we used a cell-permeable cAMP-PKA inhibitor (Rp-8-Br-cAMPS), which functions by occupying cAMP binding sites thereby preventing activation of PKA holoenzyme. Rp-8-Br-cAMPS reverses isoproterenol-mediated up-regulation of endogenous  $\text{Cav}1.2$  in cardiomyocytes isolated from non-transgenic WT mice and transgenic pWT  $\alpha_{1C}$  mice (Supplemental Figure 2A-B) (23). In transgenic AID-mutant mice cardiomyocytes, Rp-8-Br-cAMPS did not inhibit nisoldipine-resistant basal current (Supplemental Figure 2C),

ruling out the idea that AID-mutant  $\alpha_{1C}$  channels were basally PKA-phosphorylated. The integrity of the  $\beta$ -adrenergic pathway in transgenic AID-mutant mice cardiomyocytes was assessed by probing whether isoproterenol application led to phosphorylation of phospholamban, a well-known PKA target in heart (35). Western blotting indicated that phospholamban was appropriately phosphorylated at Ser<sup>16</sup> in response to isoproterenol (Supplemental Figure 2D), confirming that the  $\beta$ -adrenergic signaling pathway was intact in AID-mutant transgenic mice cardiomyocytes.

### **$\beta$ -adrenergic regulation of Ca<sub>v</sub>1.2 does not require PKA phosphorylation of $\beta$ subunits**

The simplest explanation for the necessary role of  $\alpha_{1C}$ - $\beta$  interaction in PKA modulation of Ca<sub>v</sub>1.2 is that the  $\beta$ -subunit contains phosphorylation site(s) that are vital to this regulation. Indeed, two phosphorylation sites on  $\beta_2$  C-terminus (Ser<sup>512</sup> and Ser<sup>570</sup>) were previously identified and proposed to play a role in PKA modulation of Ca<sub>v</sub>1.2 (36). However, a knock-in mouse expressing a  $\beta_2$ -subunit truncated after Pro<sup>501</sup> displayed normal PKA modulation of Ca<sub>v</sub>1.2, thus ruling out involvement of any putative C-terminal phosphorylation sites (24). Nevertheless, it remained possible that previously unappreciated phosphorylation sites N-terminal to Pro<sup>501</sup> could mediate the increased Ca<sub>v</sub>1.2 channel activity in response to activated PKA. Using both manual sequence analyses and several web-based PKA phosphorylation prediction tools (37-41), we identified 18 conserved consensus PKA phosphorylation sites in the N-terminus, SH3 and GK domains of human  $\beta_{2b}$  (residues labeled red in Supplemental Figure 3). We mutated all 18 Ser/Thr residues to Ala in human  $\beta_{2b}$ , and generated transgenic mice with inducible cardiomyocyte-specific expression of either GFP-tagged WT or 18-mutant  $\beta_{2b}$  subunits using the same bitransgenic system as in Figure 1b. The WT and mutant  $\beta_{2b}$  transgenic mice were fed doxycycline for 1 week, thus ensuring high levels of expression of the GFP-tagged  $\beta_2$  subunits (Figure 4A). We exploited the

larger size of GFP-tagged  $\beta_2$  subunits compared to endogenous  $\beta$  to determine relative expression of transgenic and native  $\beta_2$  subunits (Figure 4B). Western blot indicated that in cardiomyocytes from transgenic mice, both GFP- $\beta_2$  and GFP-mutant-  $\beta_2$  were markedly over-expressed ( $\sim 9:1$ ) compared to endogenous  $\beta_2$  (Figure 4C). Isoproterenol increased peak  $\text{Ca}_v1.2$  current by a mean of  $1.5 \pm 0.1$ -fold in GFP-WT  $\beta_2$  expressing cells and  $1.6 \pm 0.1$ -fold in GFP-mutant  $\beta_2$  expressing cells, respectively, similar to non-transgenic mice (Figure 4D-G). For both GFP-WT and GFP-mutant  $\beta_{2b}$   $\text{Ca}^{2+}$  channels, isoproterenol shifted the  $V_{\text{mid}}$  of steady-state activation by  $-7.0$  mV and  $-7.5$  mV, respectively. These data indicate that, although the  $\alpha_{1C}$ - $\beta_2$  interaction is necessary for  $\beta$ -adrenergic regulation of  $\text{Ca}_v1.2$ , direct PKA phosphorylation of  $\beta_2$  at any of the 18 consensus PKA sites is not involved.

### **$\beta$ -adrenergic regulation of cardiac contractility requires PKA regulation of $\text{Ca}_v1.2$**

We next exploited the findings that transgenic  $\beta$ -less AID-mutant  $\alpha_{1C}$  channels are insensitive to PKA modulation to probe the specific role of  $\text{Ca}_v1.2$  modulation in the positive inotropic effect of  $\beta$ -adrenergic agonists in both isolated cardiomyocytes and in the whole heart. In transgenic pWT  $\alpha_{1C}$  cardiomyocytes, with endogenous  $\text{Ca}_v1.2$  channels silenced with nisoldipine, isoproterenol produced a robust 100% increase in fractional shortening (Figure 5A, C). By contrast, this response was severely diminished in cardiomyocytes expressing transgenic  $\beta$ -less AID-mutant  $\alpha_{1C}$  channels in which isoproterenol produced a relatively meager 25% increase in fractional shortening (Figure 5B-C). Consistent with the effects of isoproterenol on phospholamban phosphorylation (Supplemental Figure 2B), isoproterenol enhanced relaxation in cardiomyocytes isolated from both pWT and AID-mutant  $\alpha_{1C}$  transgenic mice (Figure 5D).

We then assessed the role of  $\text{Ca}_v1.2$  modulation in  $\beta$ -adrenergic agonist-induced positive

inotropy at the whole organ level by inserting a pressure-transduced balloon into the left ventricle of Langendorff-perfused transgenic mice hearts. This approach enabled measurement of cardiac contractility independent of vascular or systemic effects. Hearts were paced at 400 beats per minute to remove the potentially confounding effect of heart rate variability on contractility (42). After baseline measurements, 300 nM nisoldipine was infused into the coronary arteries via the aorta to suppress endogenous Cav1.2 channel currents. In hearts from non-transgenic mice, nisoldipine markedly reduced basal cardiac contractility due to the block of endogenous Cav1.2 channels (Figure 5E). In pWT  $\alpha_{1C}$  hearts, infusion of nisoldipine yielded a comparatively weaker effect on basal contractility owing to the expression of DHP-resistant Ca<sup>2+</sup> channels (Figure 5F); a further infusion of 200 nM isoproterenol strongly increased cardiac contractility by 3.3-fold (Figure 5G,I). By contrast, using the same experimental paradigm in hearts from  $\beta$ -less AID-mutant transgenic mice, the response to isoproterenol was nearly abolished, yielding an average increase in cardiac contractility of only 1.2-fold (Figure 5H-I).

## DISCUSSION

Much of our current understanding regarding mechanisms underlying Cav1.2 trafficking and modulation derives from studies on recombinant channels reconstituted in heterologous cells. These cells lack the complex cytoarchitecture and intracellular milieu of adult cardiomyocytes. Recently, we have developed an approach that utilizes transgenic mice expressing doxycycline-inducible, cardiac-specific DHP-resistant  $\alpha_{1C}$ . Compared to knock-in mice models (43, 44), this approach is both cost-effective and rapid, and perhaps more importantly, enables us to induce brief expression of mutant channels in adults, permitting the comparison of WT and mutant  $\alpha_{1C}$  structure-function mechanisms in the absence of developmental abnormalities and heart failure. The titration of the level of Cav1.2 expression is important, as the magnitude of  $\beta$ -adrenergic stimulation of Cav1.2 is reduced with increased basal current density (27, 45-49). Stratifying the magnitude of  $\beta$ -adrenergic-mediated upregulation of Cav1.2 current by total basal current density attenuates this confounding variable (Figure 2J, 4G).

Overall, we show that in cardiomyocytes, the AID-motif is required for the high affinity interaction between  $\alpha_{1C}$  and  $\beta$  subunits, and that  $\beta$ -less Cav1.2 channels traffic to the dyad and produce currents that mediate normal E-C coupling. The AID-mutant  $\beta$ -less  $\text{Ca}^{2+}$  currents were completely refractory to PKA activation. These findings, combined with our recent studies (23), fundamentally recast our views on mechanisms underlying Cav1.2 trafficking and PKA modulation in cardiomyocytes as they show that: 1) it is possible for  $\beta$ -less channels to traffic to the cell surface, 2)  $\beta_2$  binding to  $\alpha_{1C}$  is indispensable for PKA modulation of Cav1.2, and that  $\beta$ -adrenergic regulation of Cav1.2 can be specifically attenuated by sequestering  $\beta$  subunits, 3) conserved consensus PKA phosphorylation sites in  $\alpha_{1C}$  (23) and  $\beta_{2b}$  are not required for  $\beta$ -adrenergic regulation of Cav1.2 in heart. Further, we directly show that  $\beta$ -adrenergic modulation

of Cav1.2 is critical for sympathetic augmentation of cardiac inotropy, which is essential for the fight-or-flight response.

When co-expressed with  $\alpha_1$  subunits in heterologous expression systems such as *Xenopus* oocytes or HEK cells,  $\beta$  subunits markedly augment current density by increasing membrane targeting and altering electrophysiological properties (6-8). In adult heart, however,  $\text{Ca}^{2+}$  channels can traffic to the surface membrane without binding to  $\beta$ . How  $\beta$ -less  $\alpha_{1C}$  channels traffic to the dyad in cardiomyocytes but not in a less complex system such as HEK cells is not yet clear. Although low affinity interactions between heterologously expressed  $\beta$  subunit GK and SH3 domains and the Cav2.1  $\alpha$  subunit in oocytes have been described (50), these potential interactions do not appear to be sufficient to rescue the trafficking of AID-mutant Cav1.2 channels in tsA-201 cells. Moreover, conditional knockout of *Cacnb2* in adult cardiomyocytes caused only a 29% reduction in current density (19).

Regardless of the mechanisms enabling trafficking to the cell surface,  $\beta$ -less Cav1.2 channels are functionally normal under basal conditions in adult cardiomyocytes. However, the  $\beta$ -less channels cannot be regulated by adrenergic-PKA stimulation, although the  $\beta$  subunit does not appear to be the functional target of PKA. To differentiate between the lack of  $\beta$  binding as opposed to the mutations in the AID as causative of the defect in  $\beta$ -adrenergic regulation of Cav1.2, we used the complementary approach of expressing using adenovirus, YFP-AID- and YFP-mutant AID-containing peptides in cultured adult guinea pig ventricular myocytes. The response to forskolin was markedly reduced by preventing  $\beta$  subunits from interacting with endogenous wild-type  $\alpha_{1C}$ , implying that lack of  $\beta$  binding to  $\alpha_{1C}$  is sufficient to prevent  $\beta$ -adrenergic regulation of Cav1.2 in the heart. Our studies cannot address where and when  $\beta$  subunits first interact with  $\alpha_{1C}$  subunits in the heart.

Identifying the functional PKA target is more complicated. It is likely not solely  $\alpha_{1C}$ , based upon our prior studies eliminating all conserved consensus PKA phosphorylation sites in the  $\alpha_{1C}$  subunit (23). Likewise, it is not solely  $\beta$ , based upon eliminating all conserved PKA phosphorylation sites in  $\beta_2$  (Figure 4). Thus, our findings suggest that either there is redundancy between  $\alpha_{1C}$  and  $\beta$  subunits, such that PKA phosphorylation of either subunit is sufficient to mediate adrenergic regulation of  $Ca^{2+}$  channels in the heart, or that PKA phosphorylation of the core  $Ca_v1.2$  subunits,  $\alpha_{1C}$  and  $\beta$ , are not necessary for  $\beta$ -adrenergic regulation of the  $Ca^{2+}$  influx in the heart. This can be addressed by cross-breeding the transgenic mice harboring Ala-substitutions of all PKA consensus sites in  $\alpha_{1C}$  and  $\beta_{2b}$ . Although PKA phosphorylation of  $\beta$  is not required,  $\beta$  subunits, via binding to the I-II loop, could regulate pore opening and voltage-sensor movement. The domain I S6-AID linker forms a continuous helix that may act as a rigid rod through which  $\beta$  subunits modulate channel gating (51).

The loss of  $\beta$ -adrenergic activation of  $Ca_v1.2$  correlated with a markedly attenuated  $\beta$ -adrenergic contractile response. Originally proposed by Fabiato,  $Ca_v1.2$  current has two distinct roles in E-C coupling: triggering the release of  $Ca^{2+}$  from the SR and loading the cell (and SR) with  $Ca^{2+}$  (52). The loss of adrenergic regulation of  $Ca_v1.2$  could affect both triggering of RyR2 and the loading of SR with  $Ca^{2+}$ , thereby attenuating the adrenergically-driven inotropic response. Our findings are the first to demonstrate experimentally the vital role of  $\beta$ -adrenergic stimulation of  $Ca_v1.2$  in shaping the flight-or-fight response in the heart, and validate a recently proposed mathematical model predicting that the loss of  $\beta$ -adrenergic stimulation of  $Ca_v1.2$  would markedly limited  $Ca^{2+}$  transients and contraction (53). PKA and  $Ca^{2+}$ /calmodulin-dependent protein kinase II (CaMKII) phosphorylation of RyR2 also enhances the open probability of the RyR2  $Ca^{2+}$  release channels in the SR by enhancing their sensitivity to cytosolic (54) and synchronizing SR  $Ca^{2+}$

release (55-57). It remains controversial, however, as to whether increasing the open probability of RyR2 is critically important for inotropic responses in the heart (58-60). We demonstrate that without augmented  $\text{Ca}_v1.2$  current to load the cell with additional  $\text{Ca}^{2+}$  and/or enhance RyR opening via  $\text{Ca}^{2+}$ -induced  $\text{Ca}^{2+}$  release,  $\beta$ -adrenergic agonist-induced phosphorylation of RyR2 and phospholamban does not result in substantial  $\beta$ -adrenergic augmentation of cardiac contractility.

In summary, we have found that  $\text{Ca}^{2+}$  channel  $\beta$  subunit binding to the pore-forming  $\alpha_{1C}$  subunit is not required for trafficking and function of the  $\text{Ca}^{2+}$  channel in the heart. The loss of  $\alpha_{1C}$ - $\beta_2$  binding causes marked attenuation of  $\beta$ -adrenergic induced stimulation of  $\text{Ca}_v1.2$  and inotropy. Thus, we identify a new function for  $\beta$  subunits in heart: as an essential component of the PKA-mediated augmentation of  $\text{Ca}_v1.2$  and increased cardiac contractility that occurs during the physiological fight or flight response.

## **METHODS**

### **Reagents**

Nisoldipine and Rp-8-Br-cAMPS were purchased from Santa Cruz Biotechnology. All other chemicals were acquired from Sigma.

### **Animals**

The  $\alpha_{1C}$  transgenic constructs were generated by fusing rabbit *Cacna1c* cDNA (accession X15539) to the modified murine  $\alpha$ -myosin heavy chain (MHC), tetracycline-inducible promoter (“responder” line) vector (gift of Drs. Jeffrey Robbins and Jeffrey Molkentin, University of Cincinnati, Cincinnati, OH) (61, 62). The  $\alpha_{1C}$  subunit was engineered to be both dihydropyridine (DHP)-insensitive with the substitutions T1066Y and Q1070M (32, 33) and tagged with a 3X-FLAG-epitope. We made alanine-substitutions of three conserved residues: Y467, W470 and I471 in the AID domain of rabbit  $\alpha_{1C}$  (Figure 1A). Two distinct AID-mutant  $\alpha_{1C}$  mice were created and studied. The results obtained from each of these lines were equivalent and therefore the data were pooled. The  $\beta_{2b}$  transgenic constructs were generated by ligating a N-terminal GFP-tagged human *CACNB2b* cDNA (accession # AF285239) to the tetracycline-inducible vector. These mice were bred with cardiac specific ( $\alpha$ MHC) doxycycline-regulated codon-optimized reverse transcriptional transactivator (rtTA) mice (obtained via MMRRC) (63) to generate double transgenic mice. The  $\alpha_{1C}$  transgenic animals received 0.2 g/kg doxycycline-impregnated food (Bio Serv Cat # S3888) for 1-2 days and the GFP- $\beta_{2b}$  transgenic mice received the doxycycline-impregnated food for 1 week to maximize expression.

### **Generation of adenoviral vectors and infection of guinea pig ventricular cardiomyocytes**

Replication deficient adenoviral vectors expressing AID-YFP and AIDmut-YFP were generated using the AdEasy Adenoviral Vector System (Agilent Technologies) according to the manufacturer's instructions. Briefly, sequences for AID-YFP and AIDmut-YFP were PCR-amplified and cloned into pShuttle-CMV vector. After linearization with PmeI, shuttle vectors were electroporated into BJ5183 cells containing pAdEasy-1 viral plasmid. Positive recombinants were amplified, linearized with Pac I, and transfected into AD-293 cells using the calcium phosphate precipitation method. Transfected cells were monitored for development of adenoviral plaques, after which the cells were freeze-thawed and the lysate used to infect a 10-cm dish of 90% confluent HEK293 cells. Viral expansion and purification was carried out as previously described(64).

Adult guinea pig ventricular myocytes were isolated by enzymatic digestion using a Langendorff perfusion apparatus, and cultured as previously described (27). Animal treatment and use were in accordance with a protocol approved by the Columbia University Institutional Animal Care and Use Committee. Heart cells were infected 2-3 hours after plating with 5-20  $\mu$ l of adenoviral vector stock ( $\approx 10^{11}$ – $10^{12}$  viral particles/ml).

### **Immunoprecipitation, Immunoblots and Immunofluorescence**

Cardiac lysates from 6-12-week-old doxycycline-fed transgenic mice were prepared from either whole hearts or isolated ventricular cardiomyocytes (65). Immunoprecipitations were performed in modified RIPA buffer consisting of 50 mM Tris HCl; pH 7.4, 150 mM NaCl, Triton X-100 (0.25%), 10 mM EDTA, 10 mM EGTA, 10  $\mu$ M Calpain inhibitor I, 10  $\mu$ M Calpain inhibitor II, and Complete Mini-tablets (1 per 7 ml), using anti-FLAG antibody (Sigma) overnight. Immune

complexes were collected using protein A (Amersham) for 2 h, followed by extensive washing. Proteins were size-fractionated, transferred to nitrocellulose membranes and probed with anti-FLAG antibody (Sigma), anti-tubulin antibody (Santa Cruz), custom anti- $\alpha_{1C}$  and anti- $\beta_2$  antibodies (65), and phospholamban antibodies (Badrilla). Detection was performed with a CCD camera (Carestream Imaging), and ImageQuant software was used for quantification. Isolated cardiomyocytes were fixed for 15 minutes in 4% paraformaldehyde, and indirect immunofluorescence performed using a 1:200 rabbit anti-FLAG antibody and 1:200 FITC-labeled goat-anti-rabbit antibody (Sigma). Images were acquired using a confocal microscope.

### **Cellular Electrophysiology**

Membrane currents from isolated mouse ventricular cardiomyocytes (66) were measured by the whole-cell patch-clamp method using a MultiClamp 700B amplifier and pCLAMP 10 software (Molecular Devices) as described (65). The pipette solution contained (in mM): 40 CsCl, 90 Cs gluconate, 10 BAPTA, 1 MgCl<sub>2</sub>, 4 Mg-ATP, 2 CaCl<sub>2</sub>, and 10 HEPES, adjusted to pH 7.2 with CsOH. After the isolated cardiomyocytes were adequately buffered with 10 mM BAPTA in the internal solution, the isolated cardiomyocytes were superfused with (in mM): 140 TEA-Cl, 1.8 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 glucose, and 10 HEPES, adjusted to pH 7.4 with CsOH. For experiments in tsA-201 cells, TEA-Cl was reduced to 130 mM, and BaCl<sub>2</sub> (10 mM) was used instead of CaCl<sub>2</sub>. Pipette series resistances were usually <1 M $\Omega$  after 60% compensation. Leak currents and capacitance transients were subtracted by a P/4 protocol. Voltages were corrected for the liquid junction potential of -10 mV. To measure Ca<sup>2+</sup> peak currents, the cell membrane potential was held at -50 mV and stepped to +10 mV for 350 ms every 10 seconds. To evaluate the current-voltage (I-V) relationship for Ca<sup>2+</sup> currents, the same protocol was repeated with steps between -

50 mV to +50 mV in 10 mV increments. All experiments were performed at room temperature,  $22 \pm 1^\circ$  C. The parameters of voltage-dependent activation were obtained using a modified Boltzmann distribution:  $I(V) = G_{\max} * (V - E_{\text{rev}}) / [1 + \exp((V_{\text{mid}} - V) / V_c)]$ , where  $I(V)$  is peak current,  $G_{\max}$  is maximal conductance,  $E_{\text{rev}}$  is reversal potential,  $V_{\text{mid}}$  is the midpoint, and  $V_c$  is the slope factor.

Whole-cell recordings of virally-infected cultured guinea pig ventricular myocytes were conducted at room temperature as previously described (27, 67). Patch pipettes typically had 1–2 M $\Omega$  series resistance when filled with internal solution containing (in mM): 150 cesium-methanesulfonate, 10 EGTA, 5 CsCl, 1MgCl<sub>2</sub>, 10 HEPES and 4 MgATP (pH 7.3). Cells were perfused with normal Tyrode external solution during formation of gigaohm seal. After successful break-in to the whole-cell configuration the perfusing medium was switched to an external recording solution containing (in mM): 155 N-methy-D-glucamine-aspartate, 10 4-aminopyridine, 1 MgCl<sub>2</sub>, 5 BaCl<sub>2</sub>, 10 HEPES (pH 7.4). Currents were sampled at 50 KHz and filtered at 5 KHz and leak and capacitive currents were subtracted using a P/8 protocol.

### **Fractional shortening of isolated cardiomyocytes**

Freshly isolated myocytes were superfused with a Tyrode's solution containing 1.0 mM CaCl<sub>2</sub> and 300 nM nisoldipine. Myocytes were field stimulated at 1-Hz. Percent contraction of sarcomere length was measured using the SarcLen module of Ionoptix and calculated as the difference of shortest sarcomere length during a contraction subtracted from the relaxed sarcomere length, divided by the relaxed sarcomere length, all averaged over at least 8 contractions.

### ***Ex vivo* cardiac contractility**

The cannulated hearts were retrogradely perfused on a Langendorff system with a modified Krebs solution (118.5 mM NaCl, 25 mM NaHCO<sub>3</sub>, 4.7 mM KCl, 1.2 mM MgSO<sub>4</sub>, 1.2 mM KH<sub>2</sub>PO<sub>4</sub>, 11 mM glucose, 1.8 mM Ca<sup>2+</sup>). Left ventricular pressure was measured using a balloon catheter connected to an APT-300 pressure transducer, which was connected to a PowerLab digitizer (ADInstruments). After initial assessment of cardiac contractility, 300 nM nisoldipine was perfused to silence endogenous Ca<sup>2+</sup> currents. The effects of nisoldipine on contractility were assessed after at least 3 minutes and upon stabilization of LV pressures. Thereafter, 200 nM isoproterenol was perfused with 300 nM nisoldipine for at least 3 minutes. Peak LV pressure during the 3-minute period was used for the assessment of β-adrenergic agonist stimulation.

### **Statistics**

Results are presented as mean ± SEM. For multiple group comparisons, a one-way ANOVA followed by multiple comparison testing were performed. For comparisons between two groups, an unpaired Student's *t*-test was used. Statistical analyses were performed using Prism 6 (Graphpad Software). Differences were considered statistically significant at values of  $P < 0.05$

### **Data availability**

The data and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure.

### **Study approval**

The Institutional Animal Care and Use Committee at Columbia University approved all animal experiments.

### **Author Contributions**

Conceptualization, S.O.M., H.C., and G.S.P.; Methodology, L.Y., A.K., J.K., A.K., S.I.Z., S.V. S.O.M., H.C., and G.S.P.; Investigation, L.Y., A.K., J.K., A.K., S.I.Z., B.C., S.V., G.L., A.P., D.R., S.O.M., and H.C.; Writing – Original Draft, S.O.M., H.C., and G.S.P; Writing – Review & Editing, L.Y., A.K., J.K., A.K., S.I.Z., B.C., S.V., G.L., A.P., D.R., G.S.P., H.C., and S.O.M. H.C.; Funding Acquisition, S.O.M., H.C., and G.S.P.; Resources, S.O.M., H.C., and G.S.P.

### **Acknowledgments**

This work was supported by NIH R01 HL113136 and R01 HL121253. Jared Kushner was supported by T32 HL007343; Zunaira Shuja was supported by T32HL120826.

## REFERENCES:


1. Catterall WA. Structure and regulation of voltage-gated Ca<sup>2+</sup> channels. *Annu Rev Cell Dev Biol.* 2000;16:521-55.
2. Min D, Guo F, Zhu S, Xu X, Mao X, Cao Y, et al. The alterations of Ca<sup>2+</sup>/calmodulin/CaMKII/CaV1.2 signaling in experimental models of Alzheimer's disease and vascular dementia. *Neurosci Lett.* 2013;538:60-5.
3. Peterson BZ, DeMaria CD, Adelman JP, and Yue DT. Calmodulin is the Ca<sup>2+</sup> sensor for Ca<sup>2+</sup> -dependent inactivation of L-type calcium channels. *Neuron.* 1999;22(3):549-58.
4. Erickson MG, Alseikhan BA, Peterson BZ, and Yue DT. Preassociation of calmodulin with voltage-gated Ca(2+) channels revealed by FRET in single living cells. *Neuron.* 2001;31(6):973-85.
5. Scriven DR, Dan P, and Moore ED. Distribution of proteins implicated in excitation-contraction coupling in rat ventricular myocytes. *Biophys J.* 2000;79(5):2682-91.
6. Perez-Reyes E, Castellano A, Kim HS, Bertrand P, Baggstrom E, Lacerda AE, et al. Cloning and expression of a cardiac/brain beta subunit of the L-type calcium channel. *J Biol Chem.* 1992;267(3):1792-7.
7. Castellano A, Wei X, Birnbaumer L, and Perez-Reyes E. Cloning and expression of a neuronal calcium channel beta subunit. *J Biol Chem.* 1993;268(17):12359-66.
8. Lacerda AE, Kim HS, Ruth P, Perez-Reyes E, Flockerzi V, Hofmann F, et al. Normalization of current kinetics by interaction between the alpha 1 and beta subunits of the skeletal muscle dihydropyridine-sensitive Ca<sup>2+</sup> channel. *Nature.* 1991;352(6335):527-30.
9. Bichet D, Cornet V, Geib S, Carlier E, Volsen S, Hoshi T, et al. The I-II loop of the Ca<sup>2+</sup> channel alpha1 subunit contains an endoplasmic reticulum retention signal antagonized by the beta subunit. *Neuron.* 2000;25(1):177-90.
10. Chien AJ, Zhao X, Shirokov RE, Puri TS, Chang CF, Sun D, et al. Roles of a membrane-localized beta subunit in the formation and targeting of functional L-type Ca<sup>2+</sup> channels. *J Biol Chem.* 1995;270(50):30036-44.
11. Brice NL, Berrow NS, Campbell V, Page KM, Brickley K, Tedder I, et al. Importance of the different beta subunits in the membrane expression of the alpha1A and alpha2 calcium channel subunits: studies using a depolarization-sensitive alpha1A antibody. *Eur J Neurosci.* 1997;9(4):749-59.
12. Dolphin AC. Beta subunits of voltage-gated calcium channels. *J Bioenerg Biomembr.* 2003;35(6):599-620.
13. Buraei Z, and Yang J. The beta subunit of voltage-gated Ca<sup>2+</sup> channels. *Physiological reviews.* 2010;90(4):1461-506.
14. Arikath J, and Campbell KP. Auxiliary subunits: essential components of the voltage-gated calcium channel complex. *Curr Opin Neurobiol.* 2003;13(3):298-307.
15. Weissgerber P, Held B, Bloch W, Kaestner L, Chien KR, Fleischmann BK, et al. Reduced cardiac L-type Ca<sup>2+</sup> current in Ca(V)beta2<sup>-/-</sup> embryos impairs cardiac development and contraction with secondary defects in vascular maturation. *Circ Res.* 2006;99(7):749-57.
16. Altier C, Garcia-Caballero A, Simms B, You H, Chen L, Walcher J, et al. The Cavbeta subunit prevents RFP2-mediated ubiquitination and proteasomal degradation of L-type channels. *Nature neuroscience.* 2011;14(2):173-80.

17. Fang K, and Colecraft HM. Mechanism of auxiliary beta-subunit-mediated membrane targeting of L-type (Ca(V)1.2) channels. *J Physiol*. 2011;589(Pt 18):4437-55.
18. Waithe D, Ferron L, Page KM, Chaggar K, and Dolphin AC. Beta-subunits promote the expression of Ca(V)2.2 channels by reducing their proteasomal degradation. *J Biol Chem*. 2011;286(11):9598-611.
19. Meissner M, Weissgerber P, Londono JE, Prenen J, Link S, Ruppenthal S, et al. Moderate calcium channel dysfunction in adult mice with inducible cardiomyocyte-specific excision of the cacnb2 gene. *J Biol Chem*. 2011;286(18):15875-82.
20. Cingolani E, Ramirez Correa GA, Kizana E, Murata M, Cho HC, and Marban E. Gene therapy to inhibit the calcium channel beta subunit: physiological consequences and pathophysiological effects in models of cardiac hypertrophy. *Circ Res*. 2007;101(2):166-75.
21. Kamp TJ, and Hell JW. Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. *Circ Res*. 2000;87(12):1095-102.
22. Reuter H, and Scholz H. The regulation of the calcium conductance of cardiac muscle by adrenaline. *J Physiol*. 1977;264(1):49-62.
23. Katchman A, Yang L, Zakharov SI, Kushner J, Abrams J, Chen BX, et al. Proteolytic cleavage and PKA phosphorylation of alpha1C subunit are not required for adrenergic regulation of CaV1.2 in the heart. *Proc Natl Acad Sci U S A*. 2017;114(34):9194-9.
24. Brandmayr J, Poomvanicha M, Domes K, Ding J, Blaich A, Wegener JW, et al. Deletion of the C-terminal phosphorylation sites in the cardiac beta-subunit does not affect the basic beta-adrenergic response of the heart and the Ca(v)1.2 channel. *J Biol Chem*. 2012;287(27):22584-92.
25. Lemke T, Welling A, Christel CJ, Blaich A, Bernhard D, Lenhardt P, et al. Unchanged beta-adrenergic stimulation of cardiac L-type calcium channels in Ca v 1.2 phosphorylation site S1928A mutant mice. *J Biol Chem*. 2008;283(50):34738-44.
26. Ganesan AN, Maack C, Johns DC, Sidor A, and O'Rourke B. Beta-adrenergic stimulation of L-type Ca<sup>2+</sup> channels in cardiac myocytes requires the distal carboxyl terminus of alpha1C but not serine 1928. *Circ Res*. 2006;98(2):e11-8.
27. Miriyala J, Nguyen T, Yue DT, and Colecraft HM. Role of CaVbeta subunits, and lack of functional reserve, in protein kinase A modulation of cardiac CaV1.2 channels. *Circ Res*. 2008;102(7):e54-64.
28. Chen YH, Li MH, Zhang Y, He LL, Yamada Y, Fitzmaurice A, et al. Structural basis of the alpha1-beta subunit interaction of voltage-gated Ca<sup>2+</sup> channels. *Nature*. 2004;429(6992):675-80.
29. Opatowsky Y, Chen CC, Campbell KP, and Hirsch JA. Structural analysis of the voltage-dependent calcium channel beta subunit functional core and its complex with the alpha 1 interaction domain. *Neuron*. 2004;42(3):387-99.
30. Van Petegem F, Clark KA, Chatelain FC, and Minor DL, Jr. Structure of a complex between a voltage-gated calcium channel beta-subunit and an alpha-subunit domain. *Nature*. 2004;429(6992):671-5.
31. Van Petegem F, Duderstadt KE, Clark KA, Wang M, and Minor DL, Jr. Alanine-scanning mutagenesis defines a conserved energetic hotspot in the CaValpha1 AID-CaVbeta interaction site that is critical for channel modulation. *Structure*. 2008;16(2):280-94.

32. He M, Bodi I, Mikala G, and Schwartz A. Motif III S5 of L-type calcium channels is involved in the dihydropyridine binding site. A combined radioligand binding and electrophysiological study. *J Biol Chem.* 1997;272(5):2629-33.
33. Hockerman GH, Peterson BZ, Sharp E, Tanada TN, Scheuer T, and Catterall WA. Construction of a high-affinity receptor site for dihydropyridine agonists and antagonists by single amino acid substitutions in a non-L-type Ca<sup>2+</sup> channel. *Proc Natl Acad Sci U S A.* 1997;94(26):14906-11.
34. Obermair GJ, Schlick B, Di Biase V, Subramanyam P, Gebhart M, Baumgartner S, et al. Reciprocal interactions regulate targeting of calcium channel beta subunits and membrane expression of alpha1 subunits in cultured hippocampal neurons. *J Biol Chem.* 2010;285(8):5776-91.
35. Colyer J. Phosphorylation states of phospholamban. *Ann N Y Acad Sci.* 1998;853:79-91.
36. Gerhardstein BL, Puri TS, Chien AJ, and Hosey MM. Identification of the sites phosphorylated by cyclic AMP-dependent protein kinase on the beta 2 subunit of L-type voltage-dependent calcium channels. *Biochemistry.* 1999;38(32):10361-70.
37. Neuberger G, Schneider G, and Eisenhaber F. pkaPS: prediction of protein kinase A phosphorylation sites with the simplified kinase-substrate binding model. *Biol Direct.* 2007;2:1.
38. Iakoucheva LM, Radivojac P, Brown CJ, O'Connor TR, Sikes JG, Obradovic Z, et al. The importance of intrinsic disorder for protein phosphorylation. *Nucleic Acids Res.* 2004;32(3):1037-49.
39. Zhou FF, Xue Y, Chen GL, and Yao X. GPS: a novel group-based phosphorylation predicting and scoring method. *Biochem Biophys Res Commun.* 2004;325(4):1443-8.
40. Blom N, Gammeltoft S, and Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. *Journal of molecular biology.* 1999;294(5):1351-62.
41. Obenauer JC, Cantley LC, and Yaffe MB. Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. *Nucleic Acids Res.* 2003;31(13):3635-41.
42. Kushnir A, Shan J, Betzenhauser MJ, Reiken S, and Marks AR. Role of CaMKIIdelta phosphorylation of the cardiac ryanodine receptor in the force frequency relationship and heart failure. *Proc Natl Acad Sci U S A.* 2010;107(22):10274-9.
43. Domes K, Ding J, Lemke T, Blaich A, Wegener JW, Brandmayr J, et al. Truncation of murine CaV1.2 at Asp-1904 results in heart failure after birth. *J Biol Chem.* 2011;286(39):33863-71.
44. Fu Y, Westenbroek RE, Yu FH, Clark JP, 3rd, Marshall MR, Scheuer T, et al. Deletion of the distal C terminus of CaV1.2 channels leads to loss of beta-adrenergic regulation and heart failure in vivo. *J Biol Chem.* 2011;286(14):12617-26.
45. Muth JN, Yamaguchi H, Mikala G, Grupp IL, Lewis W, Cheng H, et al. Cardiac-specific overexpression of the alpha(1) subunit of the L-type voltage-dependent Ca(2+) channel in transgenic mice. Loss of isoproterenol-induced contraction. *J Biol Chem.* 1999;274(31):21503-6.
46. Beetz N, Hein L, Meszaros J, Gilsbach R, Barreto F, Meissner M, et al. Transgenic simulation of human heart failure-like L-type Ca<sup>2+</sup>-channels: implications for fibrosis and heart rate in mice. *Cardiovasc Res.* 2009;84(3):396-406.


47. Tang M, Zhang X, Li Y, Guan Y, Ai X, Szeto C, et al. Enhanced basal contractility but reduced excitation-contraction coupling efficiency and beta-adrenergic reserve of hearts with increased Cav1.2 activity. *Am J Physiol Heart Circ Physiol*. 2010;299(2):H519-28.
48. Chen X, Zhang X, Kubo H, Harris DM, Mills GD, Moyer J, et al. Ca<sup>2+</sup> influx-induced sarcoplasmic reticulum Ca<sup>2+</sup> overload causes mitochondrial-dependent apoptosis in ventricular myocytes. *Circ Res*. 2005;97(10):1009-17.
49. Chen X, Nakayama H, Zhang X, Ai X, Harris DM, Tang M, et al. Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy. *J Mol Cell Cardiol*. 2011;50(3):460-70.
50. Maltez JM, Nunziato DA, Kim J, and Pitt GS. Essential Ca(V)beta modulatory properties are AID-independent. *Nat Struct Mol Biol*. 2005;12(4):372-7.
51. Findeisen F, and Minor DL, Jr. Disruption of the IS6-AID linker affects voltage-gated calcium channel inactivation and facilitation. *J Gen Physiol*. 2009;133(3):327-43.
52. Fabiato A. Simulated calcium current can both cause calcium loading in and trigger calcium release from the sarcoplasmic reticulum of a skinned canine cardiac Purkinje cell. *J Gen Physiol*. 1985;85(2):291-320.
53. Negroni JA, Morotti S, Lascano EC, Gomes AV, Grandi E, Puglisi JL, et al. beta-adrenergic effects on cardiac myofilaments and contraction in an integrated rabbit ventricular myocyte model. *J Mol Cell Cardiol*. 2015;81:162-75.
54. Aalkjaer C, and Nilsson H. Vasomotion: cellular background for the oscillator and for the synchronization of smooth muscle cells. *British journal of pharmacology*. 2005;144(5):605-16.
55. Kushnir A, Betzenhauser MJ, and Marks AR. Ryanodine receptor studies using genetically engineered mice. *FEBS Lett*. 2010;584(10):1956-65.
56. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblyt N, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. *Cell*. 2000;101(4):365-76.
57. Wehrens XH, Lehnart SE, Reiken SR, and Marks AR. Ca<sup>2+</sup>/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. *Circ Res*. 2004;94(6):e61-70.
58. Shan J, Kushnir A, Betzenhauser MJ, Reiken S, Li J, Lehnart SE, et al. Phosphorylation of the ryanodine receptor mediates the cardiac fight or flight response in mice. *J Clin Invest*. 2010;120(12):4388-98.
59. Muraski JA, Fischer KM, Wu W, Cottage CT, Quijada P, Mason M, et al. Pim-1 kinase antagonizes aspects of myocardial hypertrophy and compensation to pathological pressure overload. *Proc Natl Acad Sci U S A*. 2008;105(37):13889-94.
60. Eisner DA, Kashimura T, O'Neill SC, Venetucci LA, and Trafford AW. What role does modulation of the ryanodine receptor play in cardiac inotropy and arrhythmogenesis? *J Mol Cell Cardiol*. 2009;46(4):474-81.
61. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, and Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. *Circ Res*. 2003;92(6):609-16.
62. Hambleton M, York A, Sargent MA, Kaiser RA, Lorenz JN, Robbins J, et al. Inducible and myocyte-specific inhibition of PKCalpha enhances cardiac contractility and protects against infarction-induced heart failure. *Am J Physiol Heart Circ Physiol*. 2007;293(6):H3768-71.

63. Valencik ML, and McDonald JA. Codon optimization markedly improves doxycycline regulated gene expression in the mouse heart. *Transgenic Res.* 2001;10(3):269-75.
64. Colecraft HM, Alseikhan B, Takahashi SX, Chaudhuri D, Mittman S, Yegnasubramanian V, et al. Novel functional properties of Ca(2+) channel beta subunits revealed by their expression in adult rat heart cells. *J Physiol.* 2002;541(Pt 2):435-52.
65. Yang L, Katchman A, Samad T, Morrow JP, Weinberg RL, and Marx SO. beta-adrenergic regulation of the L-type Ca<sup>2+</sup> channel does not require phosphorylation of alpha1C Ser1700. *Circ Res.* 2013;113(7):871-80.
66. O'Connell TD, Rodrigo MC, and Simpson PC. Isolation and culture of adult mouse cardiac myocytes. *Methods Mol Biol.* 2007;357:271-96.
67. Xu X, Marx SO, and Colecraft HM. Molecular mechanisms, and selective pharmacological rescue, of Rem-inhibited CaV1.2 channels in heart. *Circ Res.* 2010;107(5):620-30.




**Figure 1. AID-mutant  $\alpha_{1C}$  channels trafficking and function in cardiomyocytes** (A) Schematic of rabbit cardiac  $\alpha_{1C}$  subunit topology showing  $\beta$  subunit binding to  $\alpha$ -interacting domain (AID) motif in I-II loop. WT and mutant AID motif in the I-II loop of  $\alpha_{1C}$ . (B) Schematic representation of the binary transgene system. The  $\alpha$ MHC<sub>MOD</sub> construct is a modified  $\alpha$ MHC promoter containing the *tet*-operon for regulated expression of FLAG-tagged DHP-resistant (DHP\*)  $\alpha_{1C}$ . (C) Anti-FLAG (upper) and anti- $\beta$  immunoblots (lower) of anti-FLAG antibody immunoprecipitation of cardiac homogenates of non-transgenic (NTG), pWT  $\alpha_{1C}$  and AID-mutant  $\alpha_{1C}$  mice. Representative of 3 experiments. (D) Immunostaining of pWT and AID-mutant  $\alpha_{1C}$  cardiomyocytes. Anti-FLAG and FITC-conjugated secondary antibodies, and nuclear labeling with Hoechst stain. Negative control omitted anti-FLAG antibody. Images obtained with confocal microscopy at 40X. Scale bar = 20  $\mu$ m. (E) Exemplar whole-cell  $Ca_v1.2$  currents recorded from freshly dissociated cardiomyocytes of non-transgenic (NTG), pWT and AID-mutant  $\alpha_{1C}$  transgenic mice. Pulses from -70 mV to +10 mV before (black traces) and 3 minutes after (red traces) of 300

nM nisoldipine. (F) Scatter plot showing current densities before and after 300 nM nisoldipine. Mean  $\pm$  SEM. \*,  $P < 0.05$  NTG vs. transgenic pWT  $\alpha_{1C}$ , \*\*\*\*,  $P < 0.0001$  NTG vs. transgenic AID-mutant  $\alpha_{1C}$  \*\*\*\*,  $P < 0.0001$  NTG pre-vs post-nisoldipine, \*\*\*,  $P < 0.001$  pWT or AID-mutant  $\alpha_{1C}$  pre-vs post-nisoldipine. One-way ANOVA and Dunnett's multiple comparison test. NTG: N= 8 cardiomyocytes from 5 mice, pWT: N= 21 cardiomyocytes from 7 mice, AID-mutant: N=45 cardiomyocytes from 9 mice. (G-I) Representative time courses of changes in sarcomere length after superfusion of 300 nM nisoldipine-containing solution for cardiomyocytes isolated from NTG mice (G), and pWT (H) and AID-mutant transgenic  $\alpha_{1C}$  mice. Cardiomyocytes were field-stimulated at 1-Hz. (J) Scatter plot showing percent contraction of sarcomere length in the absence and presence of nisoldipine for cardiomyocytes isolated from NTG mice, and pWT and AID-mutant  $\alpha_{1C}$  transgenic mice. NTG: N= 12 cells from 3 mice; pWT: 16 cells from 3 mice; AID-mutant: N=18 cells from 3 mice.




**Figure 2. AID-mutant  $Cav1.2$  channels lack  $\beta$ -adrenergic regulation.** (A) Normalized  $Cav1.2$  current-voltage relationships for transgenic pWT and AID-mutant  $\alpha_{1C}$  cardiomyocytes in presence of nisoldipine.  $N=19$  cardiomyocytes from 3 pWT  $\alpha_{1C}$  transgenic mice;  $N=18$  cardiomyocytes from 6 AID-mutant  $\alpha_{1C}$  transgenic mice. (B-C) Scatter dot plots of Boltzmann function parameters  $V_{mid}$  and slope ( $V_c$ ). \*\*  $P < 0.01$ , Anova and Sidak's multiple comparison test,  $N=19$  cardiomyocytes from 3 pWT  $\alpha_{1C}$  transgenic mice;  $N=18$  cardiomyocytes from 6 AID-mutant  $\alpha_{1C}$  transgenic mice. (D) Scatter dot plots of time constants of inactivation at the indicated potentials obtained from a single exponential fit.  $N=24$  pWT  $\alpha_{1C}$  cardiomyocytes from 4 mice and  $N=24$  AID-mutant  $\alpha_{1C}$  cardiomyocytes from 4 mice.  $P > 0.05$  pWT vs. AID-mutant for all voltages using Sidak's multiple comparison test. (E-F) Exemplar nisoldipine-resistant current-voltage relationships of transgenic pWT  $\alpha_{1C}$  (E) and AID-mutant  $\alpha_{1C}$  (F) acquired in the absence (black trace) and presence of 200 nM isoproterenol (red trace). (G) Diary plot of normalized nisoldipine-resistant  $I_{Ca}$  amplitude at +10 mV (normalized to 1 at 50 sec prior to isoproterenol) of pWT and AID-mutant  $\alpha_{1C}$  cardiomyocytes. Cells exposed to 300 nM nisoldipine followed by 200 nM isoproterenol in the continued presence of nisoldipine. pWT:  $N=30$  cardiomyocytes from 5 mice; AID-mutant:  $N=45$  cardiomyocytes from 7 mice.  $P < 0.0001$  by one-way ANOVA/multiple comparison at all time-points 30 sec post-isoproterenol. (H) Diary plot of normalized nisoldipine-resistant  $I_{Ca}$  amplitude at +10 mV (normalized to 1 at 50 sec, prior to forskolin) of pWT and AID-mutant  $\alpha_{1C}$  cardiomyocytes. Cells exposed to 300 nM nisoldipine followed by 10  $\mu$ M forskolin in the continued presence of nisoldipine. pWT:  $N=15$  cardiomyocytes from 2 mice; AID-mutant:  $N=20$  cardiomyocytes from 6 mice.  $P < 0.0001$  by one-way ANOVA/multiple comparison at all time-points 30 sec post-forskolin. (I) Scatter dot plot of isoproterenol or forskolin-induced fold increase in nisoldipine-resistant  $I_{Ca}$ . Mean  $\pm$  SEM. \*\*\*  $P < 0.001$ ; \*\*\*\*  $P < 0.0001$  by  $t$ -test. (J) Graph of isoproterenol and forskolin-induced increase in nisoldipine-resistant current stratified by total basal current density before nisoldipine


for pWT  $\alpha_{1C}$  and AID-mutant  $\alpha_{1C}$  transgenic mice. Lines fitted by linear regression for pWT cells for isoproterenol (black) and forskolin (red). For isoproterenol, pWT  $\alpha_{1C}$ : N=29 cardiomyocytes; AID-mutant  $\alpha_{1C}$ : N= 45 cardiomyocytes. For forskolin, pWT  $\alpha_{1C}$ : N= 17 cardiomyocytes; AID-mutant  $\alpha_{1C}$ : N= 9 cardiomyocytes.



**Figure 3.  $\beta$ -less wild-type endogenous  $Ca_V1.2$  channels are not stimulated by PKA.** (A-C) Adenovirus-induced GFP, AID-YFP and AID-mutant-YFP expression in cultured guinea pig ventricular myocytes. *Top*, exemplar confocal images from guinea pig cardiomyocytes expressing GFP, AID-YFP peptide or AID mutant-YFP peptide. *Bottom*, exemplar whole-cell  $Ba^{2+}$  currents from GFP, and YFP-expressing guinea pig ventricular cardiomyocyte before (black trace) and after (red trace) application of  $1 \mu M$  forskolin. (D-F) Current-voltage relationships from GFP, AID-YFP, and AID mutant-YFP-expressing cardiomyocytes before (black) and after (red) superfusion of  $1 \mu M$  forskolin. (G) Representative dairy plot showing time course of forskolin-induced increase in  $Ca_V1.2$  current. (H) Forskolin-induced increase in  $Ca_V1.2$  currents. \*  $P < 0.05$ , \*\*  $P < 0.01$  by one-way ANOVA and Tukey's multiple comparison test.



**Figure 4. PKA phosphorylation of Cav  $\beta$  is not required for  $\beta$ -adrenergic regulation of Cav1.2.** (A) Bright-field and GFP-image of WT and mutant  $\beta_{2b}$  expressing cardiomyocytes. Scale bar = 100  $\mu$ m. (B) Immunoblots using anti- $\beta_2$  antibody (upper) and anti-tubulin antibody of homogenates from the hearts of non-transgenic (NTG) and doxycycline-fed GFP-WT  $\beta_2$  and GFP-mutant  $\beta_2$  expressing mice. (C) Graph of densitometry of fraction of GFP- $\beta$ /total  $\beta$ . Mean  $\pm$  SEM. N=6 mice for NTG, WT and mutant  $\beta_2$ .  $P < 0.0001$  compared to non-transgenic by one-way Anova and Dunnett's multiple comparison test. (D-E) Normalized current-voltage relationships of GFP-WT  $\beta_2$  and GFP-mutant  $\beta_2$  cardiomyocytes acquired before and after superfusion of 200 nM isoproterenol. Isoproterenol shifted the  $V_{0.5}$  of steady-state activation by -7.0 mV ( $P < 0.0001$ ,  $t$ -test, N= 15) and -7.5 mV ( $P < 0.001$ ,  $t$ -test, N= 30), respectively. (F) Column scatter plot depicting the fold increase in peak current caused by isoproterenol. Mean  $\pm$  SEM. n= 36 cardiomyocytes from 5 NTG mice; N= 19 cardiomyocytes from 4 GFP-WT  $\beta_{2b}$  mice; N= 32 cardiomyocytes from 5 mutant  $\beta_{2b}$  mice.  $P = 0.55$  by one-way ANOVA. (G) Graphs of isoproterenol-induced increase in current stratified by total basal current density for cardiomyocytes isolated from non-transgenic mice (NTG), GFP-WT  $\beta_{2b}$  mice and GFP-mutant  $\beta_{2b}$  transgenic mice.



**Figure 5. Attenuated  $\beta$ -adrenergic stimulated inotropy in AID-mutant  $\alpha_{1C}$  transgenic mice.** (A-B) Cells with robust shortening induced by 1-Hz electrical stimulation in the presence of 300 nM nisoldipine were used. Isoproterenol (200 nM) was superfused with 300 nM nisoldipine. (C) Plot of isoproterenol-induced fold change in sarcomere length compared to before isoproterenol. Mean  $\pm$  SEM. N= 17 for pWT  $\alpha_{1C}$  cardiomyocytes and N=19 cardiomyocytes for AID-mutant  $\alpha_{1C}$ . \*\*\*  $P < 0.001$  by  $t$ -test. (D) Plot of isoproterenol-induced % change in  $\tau_{\text{relaxation}}$  of sarcomere length compared to before isoproterenol. Mean  $\pm$  SEM. N= 23 cardiomyocytes from 3 mice and N= 32 cardiomyocytes from 3 mice.  $P = 0.16$  by  $t$ -test. (E-F) Representative traces depicted effect of perfusion of 300 nM nisoldipine on left ventricular contraction in isolated Langendorff-perfused hearts resected from non-transgenic mice and pWT  $\alpha_{1C}$  transgenic mice. (G-H) Representative traces of nisoldipine-resistant left ventricular pressure before and during isoproterenol infusion, in hearts resected from pWT  $\alpha_{1C}$  and AID-mutant  $\alpha_{1C}$  transgenic mice. (I) Quantitative summary of  $dP/dt_{\text{max}}$  before and during isoproterenol infusion. N=7 pWT  $\alpha_{1C}$  transgenic mice; N= 11 AID-mutant  $\alpha_{1C}$  transgenic mice. \* $P < 0.05$  by  $t$ -test.